請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40190
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 呂紹俊 | |
dc.contributor.author | Ci-Shu Wong | en |
dc.contributor.author | 翁啟書 | zh_TW |
dc.date.accessioned | 2021-06-14T16:42:23Z | - |
dc.date.available | 2009-09-11 | |
dc.date.copyright | 2008-09-11 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-08-01 | |
dc.identifier.citation | 王新華, 成秉林, 張淑君 (2003) 複方柴胡煎劑治療脂肪肝的療效觀察。哈爾濱醫科大學學報 第6期。
劉娟秀 (1992) 膽固醇性脂肪肝機轉之研究。國立台灣大學醫學院生化學研究所博士論文。 賴雅芬 (2006) 魚油對於小鼠脂肪組織巨噬細胞堆積及發炎反應之影響研究。國立台灣大學醫學院生化暨分子生物學研究所碩士論文。 Abe, K., Ikeda, T., Wake, K., Sato, T., and Inoue, H. (2008). Glycyrrhizin prevents of lipopolysaccharide/D-galactosamine-induced liver injury through down-regulation of matrix metalloproteinase-9 in mice. J Pharm Pharmacol 60, 91-97. Ahmed, M.H., and Byrne, C.D. (2007). Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today 12, 740-747. Belfort, R., Harrison, S.A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006). A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355, 2297-2307. Berthou, L., Duverger, N., Emmanuel, F., Langouet, S., Auwerx, J., Guillouzo, A., Fruchart, J.C., Rubin, E., Denefle, P., Staels, B., et al. (1996). Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 97, 2408-2416. Beyer, T.P., Schmidt, R.J., Foxworthy, P., Zhang, Y., Dai, J., Bensch, W.R., Kauffman, R.F., Gao, H., Ryan, T.P., Jiang, X.C., et al. (2004). Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in Mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo. J Pharmacol Exp Ther 309, 861-868. Blaschke, F., Takata, Y., Caglayan, E., Law, R.E., and Hsueh, W.A. (2006). Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol 26, 28-40. Browning, J.D., and Horton, J.D. (2004). Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114, 147-152. Brusq, J.M., Ancellin, N., Grondin, P., Guillard, R., Martin, S., Saintillan, Y., and Issandou, M. (2006). Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47, 1281-1288. Chakravarthy, M.V., Pan, Z., Zhu, Y., Tordjman, K., Schneider, J.G., Coleman, T., Turk, J., and Semenkovich, C.F. (2005). 'New' hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab 1, 309-322. Chen, Y., Yang, L., and Lee, T.J. (2000). Oroxylin A inhibition of lipopolysaccharide-induced iNOS and COX-2 gene expression via suppression of nuclear factor-kappaB activation. Biochem Pharmacol 59, 1445-1457. Chen, Y.C., Shen, S.C., Chen, L.G., Lee, T.J., and Yang, L.L. (2001). Wogonin, baicalin, and baicalein inhibition of inducible nitric oxide synthase and cyclooxygenase-2 gene expressions induced by nitric oxide synthase inhibitors and lipopolysaccharide. Biochem Pharmacol 61, 1417-1427. Chisholm, J.W., Hong, J., Mills, S.A., and Lawn, R.M. (2003). The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res 44, 2039-2048. Chitturi, S., Farrell, G.C., Hashimoto, E., Saibara, T., Lau, G.K., and Sollano, J.D. (2007). Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol 22, 778-787. Chou, C.J., Haluzik, M., Gregory, C., Dietz, K.R., Vinson, C., Gavrilova, O., and Reitman, M.L. (2002). WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem 277, 24484-24489. Cong, W.N., Tao, R.Y., Tian, J.Y., Liu, G.T., and Ye, F. (2008). The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sci 82, 983-990. Dang, S.S., Wang, B.F., Cheng, Y.A., Song, P., Liu, Z.G., and Li, Z.F. (2007).Inhibitory effects of saikosaponin-d on CCl4-induced hepatic fibrogenesis in rats. World J Gastroenterol 13, 557-563. Davis, R.A., McNeal, M.M., and Moses, R.L. (1982). Intrahepatic assembly of very low density lipoprotein. Competition by cholesterol esters for the hydrophobic core. J Biol Chem 257, 2634-2640. Day, C.P., and James, O.F. (1998). Steatohepatitis: a tale of two 'hits'? Gastroenterology 114, 842-845. Daynes, R.A., and Jones, D.C. (2002). Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2, 748-759. De Lusong, M.A., Labio, E., Daez, L., and Gloria, V. (2008). Non-alcoholic fatty liver disease in the Philippines: comparable with other nations? World J Gastroenterol 14, 913-917. Ding, L.B., Lu, F.E., Ye, A.L., Xu, L., and Wang, K. (2006). [Effects of huanglian jiedu decoction on leptin and resistin in insulin resistive rats]. Zhongguo Zhong Xi Yi Jie He Za Zhi 26, 232-235. Diraison, F., Moulin, P., and Beylot, M. (2003). Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab 29, 478-485. Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., and Parks, E.J. (2005). Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115, 1343-1351. Fan, J.G. (2004). Evaluating the efficacy and safety of Danning Pian in the short-term treatment of patients with non-alcoholic fatty liver disease: a multicenter clinical trial. Hepatobiliary Pancreat Dis Int 3, 375-380. Foufelle, F., and Ferre, P. (2002). New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 366, 377-391. Fungwe, T.V., Cagen, L., Wilcox, H.G., and Heimberg, M. (1992). Regulation of hepatic secretion of very low density lipoprotein by dietary cholesterol. J Lipid Res 33, 179-191. Gorinstein, S., Leontowicz, H., Leontowicz, M., Krzeminski, R., Gralak, M., Delgado-Licon, E., Martinez Ayala, A.L., Katrich, E., and Trakhtenberg, S. (2005). Changes in plasma lipid and antioxidant activity in rats as a result of naringin and red grapefruit supplementation. J Agric Food Chem 53, 3223-3228. Horton, J.D., Bashmakov, Y., Shimomura, I., and Shimano, H. (1998). Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc Natl Acad Sci U S A 95, 5987-5992. Hsu, Y.L., Kuo, P.L., Tzeng, T.F., Sung, S.C., Yen, M.H., Lin, L.T., and Lin, C.C. (2008). Huang-lian-jie-du-tang, a traditional Chinese medicine prescription, induces cell-cycle arrest and apoptosis in human liver cancer cells in vitro and in vivo. J Gastroenterol Hepatol. Ibdah, J.A., Perlegas, P., Zhao, Y., Angdisen, J., Borgerink, H., Shadoan, M.K., Wagner, J.D., Matern, D., Rinaldo, P., and Cline, J.M. (2005). Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. Gastroenterology 128, 1381-1390. Joseph, S.B., Laffitte, B.A., Patel, P.H., Watson, M.A., Matsukuma, K.E., Walczak, R., Collins, J.L., Osborne, T.F., and Tontonoz, P. (2002). Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem 277, 11019-11025. Kanbara, R., Fukuo, Y., Hada, K., Hasegawa, T. & Terashi, A. (1992) The influence of sonic stress on lipid metabolism and the progress of atherosclerosis in rabbits with hypercholesterolemia—studies on the anti-atherosclerotic effect of g-oryzanol in sonic stress. Jpn. J. Atheroscler. 20: 159–163. Kim, S.H., Han, J., Seog, D.H., Chung, J.Y., Kim, N., Hong Park, Y., and Lee, S.K. (2005). Antidepressant effect of Chaihu-Shugan-San extract and its constituents in rat models of depression. Life Sci 76, 1297-1306. Kim, S.Y., Kim, H.J., Lee, M.K., Jeon, S.M., Do, G.M., Kwon, E.Y., Cho, Y.Y., Kim,D.J., Jeong, K.S., Park, Y.B., et al. (2006). Naringin time-dependently lowers hepatic cholesterol biosynthesis and plasma cholesterol in rats fed high-fat and high-cholesterol diet. J Med Food 9, 582-586. Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004). Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10, 1344-1351. Kurowska, E.M., and Manthey, J.A. (2004). Hypolipidemic effects and absorption of citrus polymethoxylated flavones in hamsters with diet-induced hypercholesterolemia. J Agric Food Chem 52, 2879-2886. Lee, M.J., Kim, M.J., Song, Y.S., Song, Y.O., and Moon, G.S. (2008). Bamboo culm extract supplementation elevates HDL-cholesterol and ameliorates oxidative stress in C57BL/6 mice fed atherogenic diet. J Med Food 11, 69-77. Letteron, P., Sutton, A., Mansouri, A., Fromenty, B., and Pessayre, D. (2003). Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 38, 133-140. Lin, C.C., Ng, L.T., Hsu, F.F., Shieh, D.E., and Chiang, L.C. (2004). Cytotoxic effects of Coptis chinensis and Epimedium sagittatum extracts and their major constituents (berberine, coptisine and icariin) on hepatoma and leukaemia cell growth. Clin Exp Pharmacol Physiol 31, 65-69. Lin, S.C., Lin, C.C., Lu, F.J., Lin, Y.H., and Chen, C.H. (1996). Protective and therapeutic effects of huanglian-jie-du-tang on hepatotoxin-induced liver injuries. Am J Chin Med 24, 219-229. Linden, D., William-Olsson, L., Ahnmark, A., Ekroos, K., Hallberg, C., Sjogren, H.P., Becker, B., Svensson, L., Clapham, J.C., Oscarsson, J., et al. (2006). Liver-directed overexpression of mitochondrial glycerol-3-phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation. FASEB J 20, 434-443. Louet, J.F., Chatelain, F., Decaux, J.F., Park, E.A., Kohl, C., Pineau, T., Girard, J., and Pegorier, J.P. (2001). Long-chain fatty acids regulate liver carnitine palmitoyltransferase I gene (L-CPT I) expression through a peroxisome-proliferator-activated receptor alpha (PPARalpha)-independent pathway. Biochem J 354, 189-197. Magana, M.M., and Osborne, T.F. (1996). Two tandem binding sites for sterol regulatory element binding proteins are required for sterol regulation of fatty-acid synthase promoter. J Biol Chem 271, 32689-32694. Mak, P.A., Kast-Woelbern, H.R., Anisfeld, A.M., and Edwards, P.A. (2002a). Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J Lipid Res 43, 2037-2041. Mak, P.A., Laffitte, B.A., Desrumaux, C., Joseph, S.B., Curtiss, L.K., Mangelsdorf, D.J., Tontonoz, P., and Edwards, P.A. (2002b). Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J Biol Chem 277, 31900-31908. Mantena, S.K., King, A.L., Andringa, K.K., Eccleston, H.B., and Bailey, S.M. (2008). Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med 44, 1259-1272. Mantena, S.K., Sharma, S.D., and Katiyar, S.K. (2006). Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther 5, 296-308. Matteoni, C.A., Younossi, Z.M., Gramlich, T., Boparai, N., Liu, Y.C., and McCullough, A.J. (1999). Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116, 1413-1419. McCullough, A.J. (2004). The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 8, 521-533, viii. Miao, B., Zondlo, S., Gibbs, S., Cromley, D., Hosagrahara, V.P., Kirchgessner, T.G., Billheimer, J., and Mukherjee, R. (2004). Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J Lipid Res 45, 1410-1417. Mikami, M., and Takikawa, H. (2008). Effect of genipin on the biliary excretion of cholephilic compounds in rats. Hepatol Res 38, 614-621. Nunez, E., Arnett, D.K., Benjamin, E.J., Liebson, P.R., Skelton, T.N., Taylor, H., and Andrew, M. (2005). Optimal threshold value for left ventricular hypertrophy in blacks: the Atherosclerosis Risk in Communities study. Hypertension 45, 58-63. Osumi, T., Wen, J.K., and Hashimoto, T. (1991). Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of rat acyl-CoA oxidase gene. Biochem Biophys Res Commun 175, 866-871. Peet, D.J., Turley, S.D., Ma, W., Janowski, B.A., Lobaccaro, J.M., Hammer, R.E., and Mangelsdorf, D.J. (1998). Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93, 693-704. Peraldi, P., Xu, M., and Spiegelman, B.M. (1997). Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest 100, 1863-1869. Podolsky DK (2001) Hepatic steatosis (fatty liver) and nonalcoholic steatohepatitis. Harrison’s Principles of Internal Medicine, 15th edition. New York: McGraw-Hill 300,1767-1768 Repa, J.J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.M., Shimomura, I., Shan, B., Brown, M.S., Goldstein, J.L., and Mangelsdorf, D.J. (2000a). Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 14, 2819-2830. Repa, J.J., Turley, S.D., Lobaccaro, J.A., Medina, J., Li, L., Lustig, K., Shan, B., Heyman, R.A., Dietschy, J.M., and Mangelsdorf, D.J. (2000b). Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289, 1524-1529. Rival, Y., Beneteau, N., Taillandier, T., Pezet, M., Dupont-Passelaigue, E., Patoiseau, J.F., Junquero, D., Colpaert, F.C., and Delhon, A. (2002). PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 435, 143-151. Rosen, E.D., Sarraf, P., Troy, A.E., Bradwin, G., Moore, K., Milstone, D.S., Spiegelman, B.M., and Mortensen, R.M. (1999). PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4, 611-617. Savage, D.B., Choi, C.S., Samuel, V.T., Liu, Z.X., Zhang, D., Wang, A., Zhang, X.M., Cline, G.W., Yu, X.X., Geisler, J.G., et al. (2006). Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 116, 817-824. Schultz, J.R., Tu, H., Luk, A., Repa, J.J., Medina, J.C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D.J., et al. (2000). Role of LXRs in control of lipogenesis. Genes Dev 14, 2831-2838. Shimano, H., Horton, J.D., Hammer, R.E., Shimomura, I., Brown, M.S., and Goldstein, J.L. (1996). Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 98, 1575-1584. Shimano, H., Horton, J.D., Shimomura, I., Hammer, R.E., Brown, M.S., and Goldstein, J.L. (1997). Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 99, 846-854. Shimano, H., Yahagi, N., Amemiya-Kudo, M., Hasty, A.H., Osuga, J., Tamura, Y., Shionoiri, F., Iizuka, Y., Ohashi, K., Harada, K., et al. (1999). Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J Biol Chem 274, 35832-35839. Shimomura, I., Matsuda, M., Hammer, R.E., Bashmakov, Y., Brown, M.S., and Goldstein, J.L. (2000). Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 6, 77-86. Stoeckman, A.K., Ma, L., and Towle, H.C. (2004). Mlx is the functional heteromeric partner of the carbohydrate response element-binding protein in glucose regulation of lipogenic enzyme genes. J Biol Chem 279, 15662-15669. Tan, N.S., Michalik, L., Noy, N., Yasmin, R., Pacot, C., Heim, M., Fluhmann, B.,Desvergne, B., and Wahli, W. (2001). Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 15, 3263-3277. Thomas, E.L., Hamilton, G., Patel, N., O'Dwyer, R., Dore, C.J., Goldin, R.D., Bell, J.D., and Taylor-Robinson, S.D. (2005). Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 54, 122-127. Tugwood, J.D., Issemann, I., Anderson, R.G., Bundell, K.R., McPheat, W.L., and Green, S. (1992). The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene. EMBO J 11, 433-439. Tulenko, T.N., and Sumner, A.E. (2002). The physiology of lipoproteins. J Nucl Cardiol 9, 638-649. Ueki, K., Kondo, T., Tseng, Y.H., and Kahn, C.R. (2004). Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A 101, 10422-10427. Unger, R.H., and Orci, L. (2002). Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 1585, 202-212. Varanasi, U., Chu, R., Chu, S., Espinosa, R., LeBeau, M.M., and Reddy, J.K. (1994). Isolation of the human peroxisomal acyl-CoA oxidase gene: organization, promoter analysis, and chromosomal localization. Proc Natl Acad Sci U S A 91, 3107-3111. Vianey-Saban, C., Mousson, B., Bertrand, C., Stamm, D., Dumoulin, R., Zabot, M.T., Divry, P., Floret, D., and Mathieu, M. (1993). Carnitine palmitoyl transferase I deficiency presenting as a Reye-like syndrome without hypoglycaemia. Eur J Pediatr 152, 334-338. Vu-Dac, N., Chopin-Delannoy, S., Gervois, P., Bonnelye, E., Martin, G., Fruchart, J.C., Laudet, V., and Staels, B. (1998). The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 273, 25713-25720. Wang, X., Sato, R., Brown, M.S., Hua, X., and Goldstein, J.L. (1994). SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 77, 53-62. Wang, Y.X., Lee, C.H., Tiep, S., Yu, R.T., Ham, J., Kang, H., and Evans, R.M. (2003). Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113, 159-170. Welch, J.S., Ricote, M., Akiyama, T.E., Gonzalez, F.J., and Glass, C.K. (2003). PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci U S A 100, 6712-6717. Yang, H.O., Ko, W.K., Kim, J.Y., and Ro, H.S. (2004). Paeoniflorin: an antihyperlipidemic agent from Paeonia lactiflora. Fitoterapia 75, 45-49. Ye, A.L., Lu, F.E., and Xu, L.J. (2006). [Effects of huanglian jiedu decoction on signal transduction of insulin receptor and insulin receptor substrate in adipose tissue of insulin resistant rats]. Zhongguo Zhong Xi Yi Jie He Za Zhi 26, 909-912. Ye, J.M., Doyle, P.J., Iglesias, M.A., Watson, D.G., Cooney, G.J., and Kraegen, E.W. (2001). Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 50, 411-417. Ye, J.M., Iglesias, M.A., Watson, D.G., Ellis, B., Wood, L., Jensen, P.B., Sorensen, R.V., Larsen, P.J., Cooney, G.J., Wassermann, K., et al. (2003). PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab 284, E531-540. Yeon, J.E., Choi, K.M., Baik, S.H., Kim, K.O., Lim, H.J., Park, K.H., Kim, J.Y., Park, J.J., Kim, J.S., Bak, Y.T., et al. (2004). Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. J Gastroenterol Hepatol 19, 799-804. Zhan, C.E., Chen, J.Y., and Pan, F. (2004). [Effect of modified chaihu shugan powder in treating patients with functional dyspepsia accompanied with depression]. Zhongguo Zhong Xi Yi Jie He Za Zhi 24, 1119-1121. Zhang, Y., Repa, J.J., Gauthier, K., and Mangelsdorf, D.J. (2001). Regulation of lipoprotein lipase by the oxysterol receptors, LXRalpha and LXRbeta. J Biol Chem 276, 43018-43024. Zuckerman, S.H., Kauffman, R.F., and Evans, G.F. (2002). Peroxisome proliferator-activated receptor alpha,gamma coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice. Lipids 37, 487-494. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/40190 | - |
dc.description.abstract | 脂肪肝,肝細胞含脂肪重量達5%以上時稱之。近年來國內成年人口脂肪肝盛行率高達26-34%。脂肪肝可分為酒精性及非酒精性,酒精性脂肪肝起因於飲酒過量,非酒精性脂肪肝則多與肥胖、糖尿病及代謝疾病等相關。近來研究顯示,有相當比例非酒精性脂肪肝會發展為肝纖維化、肝硬化甚至是肝癌。然而目前臨床上尚無令人滿意的藥物,這使得治療非酒精性脂肪肝之藥物開發有相當的空間。
本實驗室與順天堂藥廠合作,將中醫書上記載具有保肝功能之中草藥篩選可降低細胞三酸甘油酯的中草藥,我們篩選出其中兩種複方—黃連解毒湯及柴胡舒肝湯,並探討其用於治療非酒精性脂肪肝之可能性。 首先我們證實在LXR agonist—T0901317存在與否,此兩複方皆可降低HepG2細胞中三酸甘油酯含量,而以RT-PCR及real-time RT-PCR偵測HepG2中脂質代謝相關基因的mRNA後,我們發現此兩複方皆會降低SREBP-1c、FAS及ACC之mRNA表現量,因此推論它們皆藉由抑制SREBP-1c進而影響FAS及ACC的轉錄。之後我們更以Western-blot發現此兩複方皆降低細胞中FAS蛋白質含量,顯示其具有抑制脂肪酸合成的功效。 接下來我們以十週大的C57BL/6小鼠進行動物實驗,將之分為五組,分別為T0901317、T0901317 +柴胡舒肝湯、lipogenic diet (35% cornstarch +35% sucrose)、lipogenic diet+柴胡舒肝湯及control組。飼養3週後,由肝組織切片觀察,T0901317組並無脂肪肝產生,但出現肝臟血管阻塞情況,而柴胡舒肝湯在此動物模式下可舒緩肝臟血管阻塞情況。然而lipogenic diet組肝組織的三酸甘油酯及總膽固醇含量相較於control組明顯上升,伴隨血漿中AST濃度被提升,並由肝組織切片發現以macrovesicular steatosis型式為主的脂肪肝。柴胡疏肝湯在此動物模式下可降低血漿中ALT活性,並發現其可降低肝臟被提升的FAS蛋白質含量,但尚無減輕肝臟脂肪堆積的情況。 之後我們續以ob/ob小鼠為動物模式,將之分為兩組,分別為黃連解毒湯及control組,飼養2週後,control組肝組織三酸甘油酯約為前一次C57BL/6小鼠實驗control組的三倍,而總膽固醇則約為兩倍,血漿中ALT及AST活性也同時較高,肝組織切片則觀察到較嚴重microvesicular steatosis型式的脂肪肝形成 ,且有發炎現象產生。而黃連解毒湯在此動物模式下可明顯降低血漿中三酸甘油酯及AST活性,並減緩肝組織發炎現象,但無減輕肝臟脂肪堆積。 細胞實驗與動物實驗結果不甚一致,在論文中討論可能的原因及如何規劃更適合的動物模式。本篇論文所建立的研究脂肪肝之動物模式,將可成為本實驗室日後在脂肪肝研究上的參考。 | zh_TW |
dc.description.abstract | Fatty liver, is called when the fat content of liver cell is more than 5%. The prevalent rate of fatty liver is around 26% to 34% of adult in Taiwan. Fatty liver can be divided into alcoholic and non-alcoholic types. Alcoholic fatty liver is caused by alcohol abuse, and non-alcoholic fatty liver disease (NAFLD) is usually associated with obesity, type II diabetes, metabolic syndrome, etc. Recent studies suggested that some NAFLD may develop into liver fibrosis, cirrhosis or even hepatocellular carcinoma. At present, there is no satisfactory medicine for treating NAFLD. Therefore, it makes developing of medicines for treatment of NAFLD more important.
Our lab has the opportunity to collaborate with Sun Ten pharmaceutical company to identify Chinese herbal medicines that have potential to be used to treat NAFLD. Two of the Chinese herbal medicines—Hwang Lian Jiee Dwu Tong (HLJDT) and Chir Hwu Shu Gau Tong (CHSGT) which we found could decrease HepG2 cellular triglyceride. Therefore, HLJDT and CHSGT were selected to study on their potential in treating NAFLD. First, we found that in the present or absence of LXR agonist—T0901317, both HLJDT and CHSGT could decrease cellular triglyceride in HepG2. The mRNA levels of lipid metabolism related genes in HepG2 were analyzed by RT-PCR and real-time RT-PCR. The results showed that both of the two Chinese herbal medicines decreased SREBP-1c, FAS and ACC mRNA levels. The decrease of FAS in HepG2 was also shown by Western-bolt. The data suggest that HLJDT and CHSGT may decrease the transcription of FAS and ACC through suppressing SREBP-1c. Animal experiment was carried out to test the effect of CHSGT on liver fat using 10-week old C57BL/6 mice. Mice were divided into five groups: control, T0901317 (by i.p.), T0901317 +CHSGT (by i.p. and gavage), lipogenic diet and lipogenic diet +CHSGT (by gavage). After three weeks of treatment, histological analysis showed that T0901317 group did not have hepatic steatosis but showed blood vessel congestion. Relief of blood vessel congestion was observed in the liver in CHSGT treated mice. When compared with control group, the contents of hepatic triglyceride and cholesterol and plasma AST in lipogenic diet group are apparently higher. Histological analysis showed that the liver of lipogenic diet group had hepatic macrosteatosis. And CHSGT could decrease the levels of plasma ALT, and reduced the elevated FAS protein in the liver, but unable to reduce hepatic steatosis. Another animal experiment was carried out using 4-week old ob/ob mice. The ob/ob mice were divided into control and HLJDT (by gavage) groups. After two weeks of treatment, the hepatic triglyceride and cholesterol of control group were approximately three times and two times, respectively, as that of the control group in C57BL/6 mice. The levels of plasma AST and ALT were also higher in the control ob/ob mice. HE-stained liver specimens showed that the ob/ob mice had severe hepatic microsteatosis with inflammation. HLJDT could apparently decrease the level of plasma triglyceride and AST, and release inflammation, but unable to reduce hepatic triglyceride. The results of the animal studies were not in accordance with cell culture studies; however, the reasons for the inconsistent results were discussed. In addition, the animal models we used may provide our lab some useful references to study NAFLD. | en |
dc.description.provenance | Made available in DSpace on 2021-06-14T16:42:23Z (GMT). No. of bitstreams: 1 ntu-97-R95442011-1.pdf: 3367005 bytes, checksum: a2521c959bb59de92c060e8599d1b2bf (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 中文摘要 v
英文摘要 vii 縮寫對照表 ix 第一章 緒論 P1 第一節、文獻回顧 P2 第二節、研究動機與實驗目的 P13 第二章、材料與方法 P14 第一節、實驗材料 P15 第二節、HepG2細胞實驗 P16 一、細胞培養 二、以MTT assay測量細胞存活率 三、測量細胞內三酸甘油酯之含量 四、分析細胞中不同mRNA的表現量 五、以定量聚合酶連鎖反應(Quantitative-Polymerase Chain Reaction, Q-PCR)分析細胞內基因表現 六、以西方墨點法 (Western Blot)分析細胞內蛋白質表現 第三節、動物實驗 P23 一、動物模式 二、動物飼養、飼料製備、組織取樣及樣品前處理 三、血漿三酸甘油酯含量、總膽固醇含量、ALT及AST活 性之測定 四、肝臟三酸甘油酯、總膽固醇含量之測定 五、肝臟中蛋白質表現分析 六、統計分析 第三章、實驗結果 P29 第一節 HepG2細胞實驗 P30 第二節 C57BL/6 小鼠動物實驗 P34 第三節 ob/ob 小鼠動物實驗 P36 第四章 圖表 P38 第五章 討論 P61 第一節 HepG2 細胞實驗 P62 第二節 C57BL/6小鼠動物實驗 P64 第三節 ob/ob小鼠動物實驗 P72 第四節 綜合討論 P76 參考文獻 P80 | |
dc.language.iso | zh-TW | |
dc.title | 探討黃連解毒湯與柴胡舒肝湯於HepG2細胞及三個非酒精性脂肪肝小鼠模式之作用 | zh_TW |
dc.title | Studies on the effects of Hwang-Lian-Jiee-Dwu-Tong and Chir-Hwu-Shu-Gau-Tong in HepG2 cells and three mouse non-alcoholic fatty liver disease models | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林榮耀,沈雅敬,張淑芬,李明學 | |
dc.subject.keyword | 非酒精性脂肪肝,黃連解毒湯,柴胡舒肝湯,HepG2細胞, | zh_TW |
dc.subject.keyword | non-alcoholic fatty liver disease,Hwang-Lian-Jiee-Dwu-Tong,Chir-Hwu-Shu-Gau-Tong,HepG2 cell, | en |
dc.relation.page | 90 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-08-01 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 3.29 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。